Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Objectives:
Primary objectives:
To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate,
capecitabine, and dacarbazine in patients with solid tumors.
To determine the overall tumor response rate to imatinib mesylate in combination with
capecitabine and dacarbazine as first line and second line therapy in advanced metastatic
medullary thyroid carcinoma.
To determine the tolerability (toxicity) of this regimen.
Secondary objectives:
To determine the median overall survival (OS) and time to progression (TTP) for patients
treated with this combination.